BofA downgraded IGM Biosciences to Neutral from Buy with a price target of $8, down from $20. While still positive on IGM’s underlying autoimmune platform, the firm notes that the market is “currently giving little credit to companies with distant derisking events” and thinks the stock “could trade sideways over the next year” given the time needed until “truly derisking” clinical data is reported.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IGMS: